Cargando…

KEYNOTE‐025: Phase 1b study of pembrolizumab in Japanese patients with previously treated programmed death ligand 1–positive advanced non–small‐cell lung cancer

Pembrolizumab, a humanized monoclonal antibody against programmed death 1 (PD‐1), has been shown to improve overall survival (OS) in patients with previously treated advanced non–small‐cell lung cancer (NSCLC) with programmed death ligand 1 (PD‐L1) tumor proportion score (TPS) ≥1%. We report safety...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nishio, Makoto, Takahashi, Toshiaki, Yoshioka, Hiroshige, Nakagawa, Kazuhiko, Fukuhara, Tatsuro, Yamada, Kazuhiko, Ichiki, Masao, Tanaka, Hiroshi, Seto, Takashi, Sakai, Hiroshi, Kasahara, Kazuo, Satouchi, Miyako, Han, Shi Rong, Noguchi, Kazuo, Shimamoto, Takashi, Kato, Terufumi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6398876/ https://www.ncbi.nlm.nih.gov/pubmed/30618179 http://dx.doi.org/10.1111/cas.13932

Ejemplares similares

Pembrolizumab plus chemotherapy in Japanese patients with metastatic squamous non‐small‐cell lung cancer in KEYNOTE‐407
por: Sugawara, Shunichi, et al.
Publicado: (2023)

First‐line pembrolizumab vs chemotherapy in metastatic non‐small‐cell lung cancer: KEYNOTE‐024 Japan subset
por: Satouchi, Miyako, et al.
Publicado: (2020)

First‐line pembrolizumab vs chemotherapy in metastatic non‐small‐cell lung cancer: KEYNOTE‐024 Japan subset
por: Satouchi, Miyako, et al.
Publicado: (2021)

Phase 1b study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced melanoma (KEYNOTE-041)
por: Yamazaki, Naoya, et al.
Publicado: (2017)

Pembrolizumab plus pemetrexed‐platinum for metastatic nonsquamous non–small‐cell lung cancer: KEYNOTE‐189 Japan Study
por: Horinouchi, Hidehito, et al.
Publicado: (2021)

Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors
por: Shimizu, Toshio, et al.
Publicado: (2016)

Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: a subgroup analysis of the phase 3 KEYNOTE-045 trial
por: Nishiyama, Hiroyuki, et al.
Publicado: (2019)

Osimertinib for Japanese patients with T790M‐positive advanced non‐small‐cell lung cancer: A pooled subgroup analysis
por: Hirashima, Tomonori, et al.
Publicado: (2019)

Pharmacologic study (JP28927) of alectinib in Japanese patients with ALK+ non‐small‐cell lung cancer with or without prior crizotinib therapy
por: Hida, Toyoaki, et al.
Publicado: (2016)

Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1–Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042
por: Mansfield, Aaron S., et al.
Publicado: (2021)

Pembrolizumab plus chemotherapy in Japanese patients with persistent, recurrent or metastatic cervical cancer: Results from KEYNOTE‐826
por: Nishio, Shin, et al.
Publicado: (2022)

First-line pembrolizumab + chemotherapy in Japanese patients with advanced/metastatic esophageal cancer from KEYNOTE-590
por: Kojima, Takashi, et al.
Publicado: (2022)

Pembrolizumab monotherapy in Japanese patients with advanced ovarian cancer: Subgroup analysis from the KEYNOTE‐100
por: Nishio, Shin, et al.
Publicado: (2020)

Keynote 42: Pembrolizumab, PD-L1, and where to draw the line
por: Isaacs, James, et al.
Publicado: (2020)

Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006
por: Hamid, Omid, et al.
Publicado: (2021)

Phase II study of erlotinib plus tivantinib (ARQ 197) in patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer just after progression on EGFR-TKI, gefitinib or erlotinib
por: Azuma, Koichi, et al.
Publicado: (2016)

Pembrolizumab plus chemotherapy in Japanese patients with triple‐negative breast cancer: Results from KEYNOTE‐355
por: Hattori, Masaya, et al.
Publicado: (2023)

Second-line pembrolizumab versus chemotherapy in Japanese patients with advanced esophageal cancer: subgroup analysis from KEYNOTE-181
por: Muro, Kei, et al.
Publicado: (2021)

Pembrolizumab Plus Chemotherapy for Chinese Patients With Metastatic Squamous NSCLC in KEYNOTE-407
por: Cheng, Ying, et al.
Publicado: (2021)

First-line pembrolizumab ± chemotherapy for recurrent/metastatic head and neck cancer: Japanese subgroup of KEYNOTE-048
por: Takahashi, Shunji, et al.
Publicado: (2022)

Three-Year Follow-Up of an Alectinib Phase I/II Study in ALK-Positive Non–Small-Cell Lung Cancer: AF-001JP
por: Tamura, Tomohide, et al.
Publicado: (2017)

Lorlatinib in previously treated anaplastic lymphoma kinase‐rearranged non–small cell lung cancer: Japanese subgroup analysis of a global study
por: Seto, Takashi, et al.
Publicado: (2020)

Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001
por: Hamid, O, et al.
Publicado: (2019)

Keynote 407: the combination of pembrolizumab and chemotherapy cracks the shell of squamous cell lung cancer
por: Viteri, Santiago, et al.
Publicado: (2020)

Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program
por: Gangadhar, Tara C., et al.
Publicado: (2017)

A Review About Pembrolizumab in First-Line Treatment of Advanced NSCLC: Focus on KEYNOTE Studies
por: Qu, Jialin, et al.
Publicado: (2020)

Pembrolizumab plus dinaciclib in patients with hematologic malignancies: the phase 1b KEYNOTE-155 study
por: Gregory, Gareth P., et al.
Publicado: (2022)

Cost-Effectiveness Analysis of Pembrolizumab in Patients With Advanced Esophageal Cancer Based on the KEYNOTE-181 Study
por: Zhan, Mei, et al.
Publicado: (2022)

Pembrolizumab in Chinese patients with advanced melanoma: 3-year follow-up of the KEYNOTE-151 study
por: Si, Lu, et al.
Publicado: (2022)

Keynotes
Publicado: (2023)

Multiplex genomic profiling of non–small cell lung cancers from the LETS phase III trial of first-line S-1/carboplatin versus paclitaxel/carboplatin: results of a West Japan Oncology Group study
por: Okamoto, Isamu, et al.
Publicado: (2014)

Using Model‐Based “Learn and Confirm” to Reveal the Pharmacokinetics‐Pharmacodynamics Relationship of Pembrolizumab in the KEYNOTE‐001 Trial
por: Elassaiss‐Schaap, J, et al.
Publicado: (2016)

Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma: Findings of the Phase 1b KEYNOTE-028 Study
por: Cohen, Roger B., et al.
Publicado: (2018)

Pembrolizumab KEYNOTE-001: an adaptive study leading to accelerated approval for two indications and a companion diagnostic
por: Kang, S. P., et al.
Publicado: (2017)

Pembrolizumab in Patients With Microsatellite Instability–High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study
por: O'Malley, David M., et al.
Publicado: (2022)

Lenvatinib plus pembrolizumab in Japanese patients with endometrial cancer: Results from Study 309/KEYNOTE‐775
por: Yonemori, Kan, et al.
Publicado: (2022)

KEYNOTE-859: a Phase III study of pembrolizumab plus chemotherapy in gastric/gastroesophageal junction adenocarcinoma
por: Tabernero, Josep, et al.
Publicado: (2021)

Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170
por: Zinzani, Pier Luigi, et al.
Publicado: (2023)

Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma
por: Armand, Philippe, et al.
Publicado: (2023)

Patient-Reported Health-Related Quality of Life in KEYNOTE-604: Pembrolizumab or Placebo Added to Etoposide and Platinum as First-Line Therapy for Extensive-Stage SCLC
por: Kim, Hye Ryun, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_m26b76p1gcg8cv506sltepn1mm